目的探究改良括约肌间瘘管结扎术(Lift-plug)在经括约肌肛瘘(TSAF)病人治疗中的应用优势。方法回顾性收集2020年3月至2022年3月首都医科大学附属北京潞河医院110例TSAF病人临床资料,根据手术方法分为两组,传统组55例行Lift,Lift-plug组5...目的探究改良括约肌间瘘管结扎术(Lift-plug)在经括约肌肛瘘(TSAF)病人治疗中的应用优势。方法回顾性收集2020年3月至2022年3月首都医科大学附属北京潞河医院110例TSAF病人临床资料,根据手术方法分为两组,传统组55例行Lift,Lift-plug组55例行Lift-plug术。比较两组围术期指标、临床疗效、并发症、复发率及神经源性炎症因子[P物质(SP)、神经生长因子(NGF)、前列腺素E_(2)(PGE_(2))]、肠道微生态[D-乳酸、二胺氧化酶(DAO)]、肛门括约肌功能(肛门功能指数评分、Wexner尿失禁评分)。结果Lift-plug组手术时间[(20.22±3.34)min比(23.89±4.11)min]、创面愈合时间[(25.50±3.38)d比(30.31±4.56)d]、住院时间[(5.88±0.82)d比(6.42±1.03)d]短于传统组,术后1 d VAS评分[(2.41±0.35)分比(3.02±0.42)分]低于传统组(P<0.05);术后1 d Lift-plug组血清SP、NGF、PGE_(2)水平低于传统组(P<0.05);术后1 d、3 d两组D-乳酸、血浆DAO水平均差异无统计学意义(P>0.05);术后1个月、3个月Lift-plug组肛门功能指数、Wexner尿失禁评分均低于传统组(P<0.05);术后3个月,Lift-plug组治疗总有效率高于传统组(P<0.05);术后3个月两组并发症发生率及复发率比较差异无统计学意义(P>0.05)。结论Lift-plug术治疗TSAF病人可优化手术,减轻神经源性炎症反应,减轻早期疼痛,改善括约肌功能,增强临床疗效,且具有较高安全性。展开更多
BACKGROUND Anal fistula is increasingly prevalent due to modern lifestyle factors,and surgery remains the primary treatment.However,the rising incidence of antibiotic resistance,particularly to cefuroxime,complicates ...BACKGROUND Anal fistula is increasingly prevalent due to modern lifestyle factors,and surgery remains the primary treatment.However,the rising incidence of antibiotic resistance,particularly to cefuroxime,complicates perioperative management.The role of gut microbiota in influencing this resistance is not well understood.AIM To investigate the relationship between gut microbiota composition and cefuroxime resistance in anal fistula patients and to assess probiotic intervention impact.METHODS This study included 30 anal fistula patients categorized into cefuroxime-sensitive(Cefur-S)and cefuroxime-resistant(Cefur-NS)groups.Gut microbiota samples were collected during colonoscopy,and 16S ribosomal DNA sequencing was performed to analyze microbial diversity.Patients in the Cefur-NS group received a 7-day course of Clostridium butyricum tablets.Post-intervention,microbial composition and cefuroxime resistance were reassessed.RESULTS Alpha and beta diversity analyses showed no significant differences in microbial diversity between the Cefur-S and Cefur-NS groups.However,effect size analysis identified Roseburia and Butyricicoccus as dominant genera in the Cefur-S group,with higher butyrate production potentially protecting against cefuroxime resistance.Post-intervention,the Cefur-NS group showed a significant reduction in cefuroxime resistance,improved stool consistency,and reduced bowel movement frequency.CONCLUSION This study suggests that specific gut microbiota,particularly Butyricicoccus and Roseburia,may mitigate cefuroxime resistance in anal fistula patients by increasing butyrate production.Probiotic intervention targeting gut microbiota composition presents a promising strategy for reducing antibiotic resistance and improving clinical outcomes.展开更多
文摘目的探究改良括约肌间瘘管结扎术(Lift-plug)在经括约肌肛瘘(TSAF)病人治疗中的应用优势。方法回顾性收集2020年3月至2022年3月首都医科大学附属北京潞河医院110例TSAF病人临床资料,根据手术方法分为两组,传统组55例行Lift,Lift-plug组55例行Lift-plug术。比较两组围术期指标、临床疗效、并发症、复发率及神经源性炎症因子[P物质(SP)、神经生长因子(NGF)、前列腺素E_(2)(PGE_(2))]、肠道微生态[D-乳酸、二胺氧化酶(DAO)]、肛门括约肌功能(肛门功能指数评分、Wexner尿失禁评分)。结果Lift-plug组手术时间[(20.22±3.34)min比(23.89±4.11)min]、创面愈合时间[(25.50±3.38)d比(30.31±4.56)d]、住院时间[(5.88±0.82)d比(6.42±1.03)d]短于传统组,术后1 d VAS评分[(2.41±0.35)分比(3.02±0.42)分]低于传统组(P<0.05);术后1 d Lift-plug组血清SP、NGF、PGE_(2)水平低于传统组(P<0.05);术后1 d、3 d两组D-乳酸、血浆DAO水平均差异无统计学意义(P>0.05);术后1个月、3个月Lift-plug组肛门功能指数、Wexner尿失禁评分均低于传统组(P<0.05);术后3个月,Lift-plug组治疗总有效率高于传统组(P<0.05);术后3个月两组并发症发生率及复发率比较差异无统计学意义(P>0.05)。结论Lift-plug术治疗TSAF病人可优化手术,减轻神经源性炎症反应,减轻早期疼痛,改善括约肌功能,增强临床疗效,且具有较高安全性。
基金Supported by the Jiaxing Science and Technology Project,No.2023AD11016 and No.2023AD31028.
文摘BACKGROUND Anal fistula is increasingly prevalent due to modern lifestyle factors,and surgery remains the primary treatment.However,the rising incidence of antibiotic resistance,particularly to cefuroxime,complicates perioperative management.The role of gut microbiota in influencing this resistance is not well understood.AIM To investigate the relationship between gut microbiota composition and cefuroxime resistance in anal fistula patients and to assess probiotic intervention impact.METHODS This study included 30 anal fistula patients categorized into cefuroxime-sensitive(Cefur-S)and cefuroxime-resistant(Cefur-NS)groups.Gut microbiota samples were collected during colonoscopy,and 16S ribosomal DNA sequencing was performed to analyze microbial diversity.Patients in the Cefur-NS group received a 7-day course of Clostridium butyricum tablets.Post-intervention,microbial composition and cefuroxime resistance were reassessed.RESULTS Alpha and beta diversity analyses showed no significant differences in microbial diversity between the Cefur-S and Cefur-NS groups.However,effect size analysis identified Roseburia and Butyricicoccus as dominant genera in the Cefur-S group,with higher butyrate production potentially protecting against cefuroxime resistance.Post-intervention,the Cefur-NS group showed a significant reduction in cefuroxime resistance,improved stool consistency,and reduced bowel movement frequency.CONCLUSION This study suggests that specific gut microbiota,particularly Butyricicoccus and Roseburia,may mitigate cefuroxime resistance in anal fistula patients by increasing butyrate production.Probiotic intervention targeting gut microbiota composition presents a promising strategy for reducing antibiotic resistance and improving clinical outcomes.
